Article Text

Download PDFPDF

Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016
  1. Géric Maura1,2,
  2. Cécile Billionnet1,
  3. Jérôme Drouin1,
  4. Alain Weill1,
  5. Anke Neumann1,
  6. Antoine Pariente2,3
  1. 1 Department of Studies in Public Health, French National Health Insurance (Caisse Nationale de l’Assurance Maladie/Cnam), Paris, France
  2. 2 University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology - UMR 1219, Bordeaux, France
  3. 3 CHU Bordeaux, Bordeaux, France
  1. Correspondence to Dr Géric Maura; geric.maura{at}


Objectives To describe (i) the trend in oral anticoagulant (OAC) use following the introduction of non-vitamin K antagonist oral anticoagulant (NOAC) therapy for stroke prevention in atrial fibrillation (AF) patients and (ii) the current patterns of use of NOAC therapy in new users with AF in France.

Design (i) Repeated cross-sectional study and (ii) population-based cohort study.

Setting French national healthcare databases (50 million beneficiaries).

Participants (i) Patients with identified AF in 2011, 2013 and 2016 and (ii) patients with AF initiating OAC therapy in 2015–2016.

Primary and secondary outcome measures (i) Trend in OAC therapy use in patients with AF and (ii) patterns of use of NOAC therapy in new users with AF.

Results Between 2011 and 2016, use of OAC therapy moderately increased (+16%), while use of antiplatelet therapy decreased (−22%) among all patients with identified AF. In 2016, among the 1.1 million AF patients, 66% used OAC therapy and were more likely to be treated by vitamin K antagonist (VKA) than NOAC therapy, including patients at higher risk of stroke (63.5%), while 33% used antiplatelet therapy. Among 192 851 new users of OAC therapy in 2015–2016 with identified AF, NOAC therapy (66.3%) was initiated more frequently than VKA therapy, including in patients at higher risk of stroke (57.8%). Reduced doses were prescribed in 40% of NOAC new users. Several situations of inappropriate use at NOAC initiation were identified, including concomitant use of drugs increasing the risk of bleeding (one in three new users) and potential NOAC underdosing.

Conclusions OAC therapy use in patients with AF remains suboptimal 4 years after the introduction of NOACs for stroke prevention in France and improvement in appropriate prescribing regarding NOAC initiation is needed. However, NOAC therapy is now the preferred drug class for initiation of OAC therapy in patients with AF, including in patients at higher risk of stroke.

  • anticoagulation
  • dabigatran
  • rivaroxaban
  • apixaban
  • claims database
  • France

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from


  • Contributors GM, AP, CB, AN: designed the study. All authors have contributed substantially to the interpretation of results. GM, AP, AN: drafted the article. CB, JD, AN: conducted the statistical analysis. GM, AP, AN, CB, JD, AW: provided critical revision of the manuscript for important intellectual content. All authors had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Ethics approval This observational study based on the French healthcare databases was approved by the French Data Protection Agency (Commission Nationale de l’Informatique et des Libertés, Cnil) and did not require patient consents or ethics committee approval.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement Permanent access to the French healthcare databases is automatically granted to certain government agencies, public institutions and public service authorities. Temporary access for studies and research is possible upon request from the National Health Data Institute (INDS). All databases used in this study only contained anonymous patient records.

  • Patient consent for publication Not required.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.